Presentations
- TakeAim Leukemia
- Abstract Title: Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation
- Abstract Number: 2924
- Program: Oral and Poster Abstracts
- Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
- Session Date and Time: Sunday, December 10, 2023, 6:00 PM-8:00 PM
- TakeAim Lymphoma
- Abstract Title: Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma
- Abstract Number: 3143
- Program: Oral and Poster Abstracts
- Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
- Session Date and Time: Sunday, December 10, 2023, 6:00 PM-8:00 PM
- Abstract Title: Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
- Abstract Number: 4497
- Program: Oral and Poster Abstracts
- Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III
- Session Date and Time: Monday, December 11, 2023, 6:00 PM-8:00 PM
